Leveraging the Human Immune System to Create Novel Therapeutics

Pure MHC, LLC is a discovery and development company with platform technology and expertise in disease-specific (HLA Class I and Class II) target identification and validation, as well as immunotherapeutic drug development for cancer, infectious, and autoimmune diseases. Pure MHC provides contract research support to investigators in epitope validation, development, and therapeutic exploitation through expansive HLA experience, and expertise in mass spectrometry, proteomics, peptidomics, informatics, tissue culture, epitope screening & validation, peptide binding, HLA extraction, as well as the transfection, production, and purification of the company’s proprietary soluble HLA proteins.

About Us

Our mission is to support and enable the creation of novel therapeutics for the treatment of cancer, autoimmune, and infectious disease by leveraging the human leukocyte antigen (HLA) system to selectively identify and eliminate diseased cells.


Recently, Pure MHC augmented its considerable HLA expertise by upgrading our proteomics and lab equipment, establishing new proprietary workflows, and expanding our service capabilities to enable the analysis of much smaller primary tumor and healthy tissue samples. These improvements will allow Pure MHC to:

  • Extend our target discovery and validation work into indications
    that were previously unable to analyze due to a lack of adequate
    tissue samples.
  • Focus effort on the development of companion diagnostics for
    HLA targeting therapies to empower non-invansive patient
    qualification for clinical trials or for approved treatment regimens.

Featured News

April 6, 2022 - Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies

Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC’s proprietary offering of MHC peptide targets for oncology with Myrio’s revolutionary Retained Display™ (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

  • “Myrio’s platform is not just an outstanding scientific fit, the collaboration represents a unique and exciting way for Pure MHC to deploy its novel target assets strategically.”

Kris Looney

President, Pure MHC